AWM reports 4.2% stake in CervoMed (405,165 shares)
AWM Investment Company, Inc. amended a Schedule 13G to report beneficial ownership of 405,165 shares (or share-equivalents) of CervoMed Inc., representing 4.2% of the class.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
AWM Investment Company, Inc. amended a Schedule 13G to report beneficial ownership of 405,165 shares (or share-equivalents) of CervoMed Inc., representing 4.2% of the class. The filing explains AWM holds sole voting and dispositive power over those positions through its advisory role to three funds, with a detailed split of 235,126, 68,748 and 101,291 warrants held by the named funds. The amendment was signed on 04/07/2026.
Insights
Routine beneficial-ownership amendment reporting a sub-5% stake via adviser-controlled funds.
AWM's amendment clarifies voting and dispositive power over 405,165 shares (or warrants) through its advisory relationships with three funds. The filing lists the per-fund breakdown: 235,126, 68,748, and 101,291.
Certain governance watchers note that holdings under 5.0% are commonly reported as informational; the filing affirms advisory control and lists principals involved. No transaction prices, proceeds, or transfer dates are provided in the excerpt.
Key Figures
Key Terms
beneficially owned regulatory
sole voting power regulatory
dispositive power regulatory
warrants financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stake does AWM report in CervoMed (CRVO)?
How is the 405,165 position allocated across AWM's funds?
When was the Schedule 13G/A amendment signed?
AI-generated analysis. How Rhea-AI works. Not financial advice.